Xocova / Ensitrelvir for Post-Exposure Prophylaxis of COVID-19

As of August 2026, MARA’s assessment finds Xocova / Ensitrelvir’s reimbursement risk concentrated in care pathway integration, with evidence quality and robustness a strength; the current MARA Rating and full rationale are available in the report.

The assessment also weighs safety and adverse effects: what harms arrive alongside the benefit, which payers set against the gains before funding a treatment. The strength recorded in evidence quality and robustness carries weight because that domain asks how solid the underlying evidence is on its own terms — trial design, size and endpoints — before any question of price is reached.

Infectious Diseases

This rating sits within MARA’s Infectious Diseases coverage, alongside 12 other independently assessed treatments in the same area.

What payers will ask

Is the clinical benefit the kind payers reward? — Clinical effectiveness

The SCORPIO-PEP trial demonstrated a significant reduction in symptomatic COVID-19 with ensitrelvir compared to placebo, with a risk ratio of 0.33 (95% CI 0.22-0.49; P<0.001) in the primary mITT population. This indicates a clear clinical advantage in preventing short-term symptomatic COVID-19.

Does the economic case hold at the expected price? — Cost effectiveness

No economic model, ICER, or cost-utility analysis was identified for ensitrelvir PEP.

Is there quality-of-life evidence payers weigh? — Quality of life

No PEP-specific validated HRQoL data or utility values were identified in the reviewed sources.

Does the safety profile hold up for payers? — Safety and Adverse Effects

Short-term adverse events were similar between ensitrelvir and placebo groups, with serious adverse events occurring in 0.2% of participants in both groups. This indicates acceptable safety with notable AEs requiring monitoring.

Was the drug compared against what payers expect? — Comparator Selection

The trial used placebo as a comparator, which is appropriate given the lack of a successful oral antiviral PEP standard at the time of trial initiation.

Is the population defined the way payers need it? — Patient Population and Subgroups

The trial included a diverse population across multiple countries, but had limitations such as exclusion of recently vaccinated individuals, pregnant/lactating persons, and limited representation of immunocompromised participants.

Does the drug fit how care is delivered and paid for? — Care Pathway Integration

The trial required specific diagnostic processes and monitoring for drug interactions and pregnancy, indicating moderate pathway changes needing planning and some investment.

Are the wider system costs understood? — Resource Use and Cost Implications

No budget-impact or resource information was presented in the reviewed sources.

Would the evidence survive payer scrutiny? — Evidence Quality and Robustness

The evidence is based on a large, multinational, randomized, double-blind, placebo-controlled phase 3 trial with a precise primary effect. However, there are gaps in patient-centered and economic outcomes.

How exposed is the case to uncertainty? — Uncertainty, Sensitivity, and Broader Impacts

While the primary endpoint is statistically robust, there is high uncertainty regarding severe outcomes, special populations, and economic impacts.

This rating replaces the earlier June 2026 rating of the same drug and indication — still on the record here.

Request the current rating

Be alerted when this rating changes:

Related Reimbursement Risk Assessments

Full Legal Disclaimer and Usage Terms

The MARA Rating® is an independent opinion of a drug’s market access pharma risk profile and is provided for informational purposes only—not as investment, medical, legal or any other type of advice. See our full disclaimer here.